Table 2.
Cost per TB case prevented and cost/QALY gained comparing 3HP with direct observation by a health care worker vs. 9H*
| Mean cost/patient (2.5%, 97.5%) | Mean QALY loss/1000 patients (2.5%, 97.5%) | Mean TB cases/1000 patients (2.5%, 97.5%) | Incremental cost/TB case prevented (2.5%, 97.5%) | Incremental/life year gained (2.5%, 97.5%) | |
|---|---|---|---|---|---|
| Health system perspective | |||||
| Regimen | |||||
| 9H | 511 (497, 522) | 44 (40, 47) | 9.1 (8.5, 9.8) | Reference | Reference |
| 3HP | 623 (616, 632) | 19 (17, 22) | 3.9 (3.5, 4.4) | 21 525 (16 807, 28 520) | 4 565 (3 584, 5 965) |
| Societal perspective | |||||
| Regimen | |||||
| 9H | 705 (691, 718) | 44 (40, 47) | 9.1 (8.5, 9.8) | Reference | Reference |
| 3HP | 728 (719, 737) | 19 (17, 22) | 3.9 (3.5, 4.4) | 4 294 (1 156, 8 908) | 911 (268, 1 826) |
*
Base case results using input values given in Table 1. Simulation run using 100 000 simulated individuals for each regimen with an analytic horizon of 20 years. All costs and health outcomes have been discounted at an annual rate of 3%. Costs are in 2010 US dollars.
TB = tuberculosis; QALY = quality-adjusted life year; 3HP = 3 months of weekly isoniazid plus rifapentine; 9H = 9 months of daily, self-administered isoniazid.